Tissue Factor and Tissue Factor Pathway Inhibitor in Chronically Inflamed Gallbladder Mucosa

Table 1

Clinical and demographic data.

	Cholecystitis (n = 54)
Age, y	57.3 ± 16.2
Sex, male/female	10/44
Hypertension, n (%)	31 (57.4)
Diabetes mellitus, n (%)	5 (9.3)
Coronary artery disease, n (%)	15 (27.8)
BMI*, kg/m^2	26.1 ± 4.7
Fibrinogen, g/L	5.5 ± 1.4
Bilirubin, U/L, median (1st–3rd quartiles)	11.7 (8.3–21.1)
ALT*, U/L, median (1st–3rd quartiles)	46 (28–93.5)
AST*, U/L, median (1st–3rd quartiles)	44 (28–61)
GGTP*, U/L, median (1st–3rd quartiles)	32 (18–56)
ALP*, U/L	77.7 ± 24.7

∗BMI: body mass index; *ALT: alanine aminotransferase; *AST: aspartate aminotransferase; *GGTP: γ-glutamyltransferase; *ALP: alkaline phosphatase.